EDP305, in a phase 2 randomized, double-blind, placebo-controlled, dose-ranging trial (ARGON-1), reduced liver fat content and decreased ALT in non-cirrhotic biopsy-proven MASH patients treated during a 12-week period [305]. Here, GPT is linked to metabolic dysfunction-associated steatohepatitis.